Top Pharmaceutical Companies in Los Angeles, CA (92)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.
Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.
Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.
Procter & Gamble Company is an American multi-national consumer goods corporation. P&G was founded over 180 years ago as a soap and candle company. Today, we’re the world’s largest consumer goods company and home to iconic, trusted brands, including Always®, Charmin®, Braun®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Oral B®, Pantene®, Pampers®, Tide®, and Vicks®. The design, development, growth and...
Procter & Gamble's Top Stability & Growth Strengths
Strong Market Position & Advantage: P&G is consistently characterized as the clear industry leader with dominant positions across core categories, anchored by flagship brands like Tide, Pampers, Gillette, Crest, and Oral‑B. Multiple sources in the provided materials frame it as leading peers across home care, baby/feminine, grooming, and oral care.
Innovation-Driven Growth: The company is repeatedly recognized for leadership in product innovation and is advancing new formats and data‑driven operations to sustain momentum. References cite top‑ranked innovation in household products for multiple consecutive years and highlight launches such as new detergent formats.
Resilient & Sustainable Growth: Recent updates indicate a return to positive unit volumes with modest organic sales and EPS increases, alongside reaffirmed low single‑digit growth guidance. Dividend increases and ongoing cash returns are emphasized as continuing, underscoring a steady, durable profile.
Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive...
TIENS Group is a global multinational conglomerate founded in 1995 by Li Jinyuan in Tianjin, China. The company specializes in biotechnology, health management, and wellness, operating in over 190 countries. It offers a wide range of dietary supplements, healthcare equipment, and beauty products, aiming to improve global health by integrating nature with modern science and technology to provide a better...
ABO Holdings focuses on collecting medical-grade source blood plasma for biotherapeutic pharmaceutical clients. The collected plasma is used to manufacture plasma-protein-based injectable therapies for patients. Its stated mission is to deliver a customer-focused donor experience while supplying plasma for lifesaving treatments. ABO Plasma describes itself as part of a group of independent blood plasma collectors, with expertise across licensing, operations,...
U.S. Dermatology Partners is one of the largest physician-owned dermatology practices in the United States, providing premier medical, surgical, and cosmetic skin care to over two million patients annually. With more than 130 locations across nine states, the organization focuses on patient-first care, combining the personalized experience of private practice with a coordinated network of specialized physicians and national thought...
American Regent, Inc., a Daiichi Sankyo Group Company, is a leading manufacturer of generic and branded specialty sterile injectable products. Dedicated to improving human and animal health, the company develops, manufactures, and supplies high-quality injectables for healthcare providers, clinics, and hospitals across the United States and Canada. Their expansive portfolio includes a strong focus on IV iron therapy and other...
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts,...
Alcon's Top Stability & Growth Strengths
Strong Market Position & Advantage: The business is positioned as a global leader in eye care with meaningful share in contact lenses and one of the largest installed bases in ophthalmic surgical equipment, supporting durable demand across geographies. Scale across Vision Care and Surgical also supports recurring revenue via consumables tied to the installed base.
Resilient & Sustainable Growth: Revenue is described as growing year over year with guidance calling for continued mid-single-digit constant-currency sales growth into 2026, supported by steady demand for essential procedures like cataract surgery. The company is also positioned to outpace broader eye-care market growth expectations per the provided outlook.
Healthy Cash Flow: Cash generation is described as strong, with operating cash flow and free cash flow at sizable levels that support ongoing investment and shareholder returns. This cash profile provides resilience against near-term cost headwinds and funding for launches and efficiency programs.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have...
PolyPeptide is a global Contract Development and Manufacturing Organization (CDMO) specializing in the development and manufacturing of peptide-based active pharmaceutical ingredients (APIs) and oligonucleotides. Serving pharmaceutical and biotech customers worldwide, the company supports the creation of therapies for metabolic diseases, cancer, and neurological disorders, contributing to the health of millions of patients through deep technical expertise and GMP-quality production.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market position is reinforced by being the largest pharmaceutical company in Asia, a consistent top‑15–20 global player by revenue, and operations across roughly 80 countries.
Innovation-Driven Growth: Innovation momentum is evident through a first‑in‑class FDA‑approved narcolepsy treatment and positive late‑stage results for oveporexton and zasocitinib. Multiple priority reviews and planned launches further support the pipeline.
Profitability: Profitability is strengthening with a sharp increase in net profit and a significant rise in operating profit, accompanied by an upgraded full‑year outlook. Cost discipline and transformation initiatives are also helping protect earnings while investment rises.
Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases.
CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically...
Meissner manufactures advanced microfiltration and single-use systems. Focused on fluid technology and innovation, we leverage our R&D efforts to offer our clients products that deliver advanced processing and fluid handling solutions for pharmaceutical and biopharmaceutical manufacturing. To find out more about Meissner, visit www.meissner.com. If you are interested in pursuing a career at Meissner, please visit www.meissner.com/careers.
Gemelli is a biotechnology company that specializes in the microbiome, and IBS diagnostics.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
Lumena Pharmaceuticals develops oral therapeutics for rare liver diseases to improve liver function and relieve disease symptoms.
TAE Life Sciences is a biotechnology company developing biologically targeted radiation therapy for cancers that are difficult to treat. Its BNCT platform combines targeted boron-10 drugs with an accelerator-based neutron beam system, aiming to focus cancer-killing radiation at the cellular level while limiting effects on surrounding healthy tissue. The company is developing both the drug candidates and the neutron system;...
Phillips 66's Top Stability & Growth Strengths
Profitability: Earnings are shown at multi‑billion-dollar levels in strong quarters, including about $5.6 billion in Q3 2026 and another third quarter with $5.62 billion, indicating robust profit generation. High refinery utilization and solid midstream volumes are cited as supporting these results.
Market Expansion: Asset and footprint growth spans midstream and retail, with the Coastal Bend pipeline slated to expand from 225,000 to 350,000 bpd, a 300 MMcfd Iron Mesa gas plant due in 2027, and the branded network surpassing 7,000 sites after adding 500+ in 2025. Portfolio moves such as acquiring the remaining 50% of WRB Refining LP and advancing export and fractionation capacity reinforce this expansion.
Cost & Operational Efficiency: Operations run at high efficiency, highlighted by ~98% crude capacity utilization, record Central Corridor throughput, and maximum use of export infrastructure like the Freeport LPG dock. Capacity upgrades in 2026, including a 23% Sweeny fractionation increase and a 15% Freeport LPG export lift, further strengthened operating performance.
Anton Paar develops, produces, distributes and provides support for analytical instruments used in research, development and quality control worldwide. Ever since Mr. Anton Paar founded his one-man workshop in 1922, the Austrian based company has continuously found new ways to merge high-precision engineering with scientific curiosity. The company currently has more than 3500 employees and is active in over 170...


































